GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entera Bio Ltd (NAS:ENTX) » Definitions » PB Ratio

Entera Bio (Entera Bio) PB Ratio

: 6.86 (As of Today)
View and export this data going back to 2018. Start your Free Trial

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-19), Entera Bio's share price is $2.01. Entera Bio's Book Value per Share for the quarter that ended in Dec. 2023 was $0.29. Hence, Entera Bio's PB Ratio of today is 6.86.

Warning Sign:

Entera Bio Ltd stock PB Ratio (=7.75) is close to 2-year high of 8.51

The historical rank and industry rank for Entera Bio's PB Ratio or its related term are showing as below:

ENTX' s PB Ratio Range Over the Past 10 Years
Min: 1.01   Med: 3.6   Max: 19.33
Current: 6.86

During the past 9 years, Entera Bio's highest PB Ratio was 19.33. The lowest was 1.01. And the median was 3.60.

ENTX's PB Ratio is ranked worse than
86.74% of 1312 companies
in the Biotechnology industry
Industry Median: 2.385 vs ENTX: 6.86

During the past 12 months, Entera Bio's average Book Value Per Share Growth Rate was -28.20% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -6.40% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -16.30% per year.

During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Entera Bio was -3.90% per year. The lowest was -15.10% per year. And the median was -6.40% per year.

Back to Basics: PB Ratio


Entera Bio PB Ratio Historical Data

The historical data trend for Entera Bio's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entera Bio Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.21 3.03 3.60 1.79 2.05

Entera Bio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.79 3.31 2.95 3.36 2.05

Competitive Comparison

For the Biotechnology subindustry, Entera Bio's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Entera Bio PB Ratio Distribution

For the Biotechnology industry and Healthcare sector, Entera Bio's PB Ratio distribution charts can be found below:

* The bar in red indicates where Entera Bio's PB Ratio falls into.



Entera Bio PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Entera Bio's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=2.01/0.293
=6.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Entera Bio  (NAS:ENTX) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Entera Bio PB Ratio Related Terms

Thank you for viewing the detailed overview of Entera Bio's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Entera Bio (Entera Bio) Business Description

Traded in Other Exchanges
Address
Minrav Building - Fifth Floor, Kiryat Hadassah, Jerusalem, ISR, 9112002
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
Executives
Haya Taitel director KIRYAT HADASSAH, MINRAV BUILDING, 5TH FLOOR, JERUSALEM L3 9112002
Miranda Jayne Toledano director C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135
Gerald M Lieberman director C/O ALLIANCE CAPITAL, 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Sean Ellis director KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002
Dana Yaacov-garbeli officer: Israel CFO KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002
Phillip Schwartz director, officer: President of R&D C/O ENTERA BIO LTD., KIRYAT HADASSAH, MINRAV BUILDING, 5TH FL, JERUSALEM L3 9112002
Ramesh Ratan officer: U.S.based CFO KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002
Ron Mayron director 22A ORANIM ST, HOD HASHARON L3 4526333
Spiros Jamas director, officer: Chief Executive Officer
Gerald M Ostrov director 41 WATERVIEW, LONG BRANCH NJ 07740
Yonatan Malca director KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002
Roger Garceau director 550 HILLS DRIVE, BEDMINSTER NJ 07921
Hillel Galitzer officer: Chief Operating Officer KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002
Santora Arthur C Ii officer: Chief Medical Officer KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002

Entera Bio (Entera Bio) Headlines

From GuruFocus